Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-0843

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study ; volume:79 ; number:2 ; day:5 ; month:1 ; year:2017 ; pages:339-351 ; date:2.2017
Cancer chemotherapy and pharmacology ; 79, Heft 2 (5.1.2017), 339-351, 2.2017

Keyword: Krebs
Onkologie

Creator: Sarantopoulos, John

Contributor: Mita, Alain C.
He, Aiwu
Wade, James L.
Hsueh, Chung-Tsen
Morris, John C.
Lockhart, A. Craig
Quinn, David I.
Hwang, Jimmy
Mier, James
Zhang, Wenping
Wack, Claudine
Yin, Jian
Clot, Pierre-François
Rixe, Olivier
SpringerLink (Online service)

DOI: 10.1007/s00280-016-3210-8

URN: urn:nbn:de:1111-201702278680

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:47 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Sarantopoulos, John
Mita, Alain C.
He, Aiwu
Wade, James L.
Hsueh, Chung-Tsen
Morris, John C.
Lockhart, A. Craig
Quinn, David I.
Hwang, Jimmy
Mier, James
Zhang, Wenping
Wack, Claudine
Yin, Jian
Clot, Pierre-François
Rixe, Olivier
SpringerLink (Online service)

Other Objects (12)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach

What does a modified-Fibonacci dose-escalation actually correspond to?

Phase I dose-escalation oncology trials with sequential multiple schedules

PK/PD modeling supports the dose-escalation decision in VIKING

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach

What does a modified-Fibonacci dose-escalation actually correspond to?

Phase I dose-escalation oncology trials with sequential multiple schedules

PK/PD modeling supports the dose-escalation decision in VIKING

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach

What does a modified-Fibonacci dose-escalation actually correspond to?

Phase I dose-escalation oncology trials with sequential multiple schedules

PK/PD modeling supports the dose-escalation decision in VIKING

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach

What does a modified-Fibonacci dose-escalation actually correspond to?

Phase I dose-escalation oncology trials with sequential multiple schedules

PK/PD modeling supports the dose-escalation decision in VIKING

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach

What does a modified-Fibonacci dose-escalation actually correspond to?

Phase I dose-escalation oncology trials with sequential multiple schedules

PK/PD modeling supports the dose-escalation decision in VIKING

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach

What does a modified-Fibonacci dose-escalation actually correspond to?

Phase I dose-escalation oncology trials with sequential multiple schedules

PK/PD modeling supports the dose-escalation decision in VIKING

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Related objects

Reset password